Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2008

Intradigm Licenses siRNA IP from UMass Medical

  • Intradigm has licensed intellectual property covering certain efficacy-enhancing structural elements of siRNA from the University of Massachusetts Medical School.

    The licensed technology will allow Intradigm to incorporate novel siRNA sequences into its RNAi delivery systems. This IP includes parameters for the structural modifications for siRNAs including the Zamore Design Rules that improve the potency and efficacy of RNAi therapeutics, according to the company.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »